Filing Overview
This Form 8-K was filed by Anzu Special Acquisition Corp I, not Envoy Medical, and reports events occurring on April 14, 2021. The filing relates to the SPAC’s partial exercise of its IPO over-allotment option. The report was signed on April 20, 2021.
Business Context and Transaction
Anzu completed its initial public offering on March 4, 2021, issuing 42,000,000 units at $10.00 per unit. Each unit consisted of one share of Class A common stock and one-third of a redeemable warrant.
- Initial IPO gross proceeds: $420.0 million.
- Initial private placement: 12,400,000 warrants sold to the sponsor at $1.00 per warrant, generating approximately $12.4 million.
- Partial over-allotment exercise: 500,000 additional units sold on April 14, 2021 at $10.00 per unit, generating $5.0 million of gross proceeds.
- Additional private placement: 100,000 warrants sold concurrently at $1.00 per warrant, generating $0.1 million.
- The filing states that $425.0 million of net proceeds from the units and private placement warrants was deposited into a U.S.-based trust account for public stockholders.
Financial Metrics and Liquidity
| Metric | Reported amount |
|---|---|
| IPO units issued | 42.0 million initially; 0.5 million additional units |
| IPO price per unit | $10.00 |
| Total IPO gross proceeds | $425.0 million |
| Total private placement warrants | 12.5 million |
| Total private placement proceeds | Approximately $12.5 million |
| Trust account balance stated in filing | $425.0 million of net proceeds |
The filing does not provide revenue, operating profit, net income, cash flow, margins, debt balances, or recurring liquidity metrics. It also does not provide a clear reconciliation between total gross proceeds from the IPO and warrant placements and the $425.0 million deposited in the trust account.
Material Changes, Outlook, and Risks
The material change during the reporting period was the partial exercise of the underwriters’ over-allotment option and the related issuance of additional private placement warrants. The filing does not provide business guidance, management commentary, acquisition timing, target-company details, or updated risk factors.
The warrants are exercisable for Class A common stock at $11.50 per share, subject to specified adjustments. The filing indicates that the trust account is maintained for the benefit of public stockholders, but it does not describe any subsequent business combination or contingency.
Investor Verification Items
- Confirm that the registrant is Anzu Special Acquisition Corp I rather than Envoy Medical.
- Verify the stated $425.0 million trust account balance and the filing’s use of the term “net proceeds.”
- Review Exhibit 99.1, the pro forma balance sheet dated March 4, 2021.
- Confirm the final number of units, public shares, warrants, and sponsor warrants outstanding after the partial over-allotment exercise.
- Review subsequent filings for a business combination, redemption terms, trust-account restrictions, and related liquidity developments.